Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434613 | 0.86 | OPRD1 (0.54) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL16330572 | 0.86 | OPRD1 (0.59) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL29434521 | 0.85 | OPRD1 (0.60) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL29434544 | 0.83 | OPRD1 (0.61) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29434561 | 0.79 | OPRD1 (0.47) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL16330513 | 0.78 | GRIA1 (0.55) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL31238560 | 0.78 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8441334 | 0.77 | CTSS (0.68) | — | |
| SCHEMBL9724062 | 0.77 | GRIA1 (0.59) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL30493746 | 0.76 | GRIA1 (0.61) | OPRD1OPRM1OPRK1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | GENERATION BIO CO. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | STING1, DCLRE1B, DCLRE1A | OPRD1 4604/4885OPRM1 4425/4885OPRK1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.